Takeda expands its ADC and immuno-oncology pipeline as Innovent deal closes
The $11bn collaboration with the Chinese biopharma company gives Takeda…
The $11bn collaboration with the Chinese biopharma company gives Takeda the rights to several next-generation candidates.





